For over a century, immunologists assumed that inflammation simply faded away once the offending stimulus was cleared — a passive dilution of pro-inflammatory signals. Then, in the early 2000s, Charles Serhan’s laboratory at Harvard demonstrated something radical: resolution of inflammation is an active, genetically programmed process orchestrated by a distinct class of lipid mediators biosynthesized from omega-3 fatty acids. These molecules — resolvins, protectins, and maresins — don’t just turn off inflammation; they actively reprogram immune cells to clear debris, repair tissue, and restore homeostasis.
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are a family of endogenous lipid signaling molecules enzymatically derived from polyunsaturated fatty acids — primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with a smaller subset derived from arachidonic acid (the lipoxins). They were first identified by Charles N. Serhan and colleagues during studies of self-limited inflammatory exudates, where they observed novel lipid mediators appearing precisely at the resolution phase rather than the initiation phase of inflammation.[1]
The major SPM families include the E-series resolvins (RvE1, RvE2, RvE3) derived from EPA; the D-series resolvins (RvD1–RvD6) derived from DHA; protectins (PD1/NPD1) also derived from DHA; maresins (MaR1, MaR2) biosynthesized by macrophages from DHA; and the classical lipoxins (LXA4, LXB4) derived from arachidonic acid. Each family acts through specific G-protein-coupled receptors and operates at picomolar to nanomolar concentrations — orders of magnitude lower than classical eicosanoids like prostaglandins.[1]
How SPMs Work
Biosynthetic Class Switching: During acute inflammation, a remarkable lipid mediator class switch occurs. Initially, arachidonic acid is metabolized into pro-inflammatory prostaglandins (PGE2, PGD2) and leukotrienes (LTB4). But PGE2 and PGD2 themselves induce expression of 15-lipoxygenase in neutrophils, which then shifts the cell toward biosynthesis of lipoxins and resolvins. This temporal switch from pro-inflammatory to pro-resolving mediators is the molecular signature of programmed resolution.[1]
Macrophage Reprogramming: Perhaps the most consequential action of SPMs is the polarization of macrophages from the pro-inflammatory M1 phenotype toward the pro-resolving M2 phenotype. Resolvin D1 (RvD1) acting through the ALX/FPR2 and GPR32 receptors, and Maresin 1 (MaR1) acting through LGR6, dramatically enhance macrophage efferocytosis — the clearance of apoptotic neutrophils and cellular debris that is essential for resolution.[2]
Neutrophil Trafficking Control: SPMs do not suppress neutrophil function broadly like glucocorticoids. Instead, they specifically limit further neutrophil infiltration into inflamed tissue while preserving host defense against pathogens. Resolvin E1 (RvE1) signals through the ChemR23 receptor on neutrophils to reduce transendothelial migration without compromising bacterial killing — a critical distinction from immunosuppressive drugs.[3]
Resolution of Pain and Tissue Repair: SPMs also act on sensory neurons and stromal cells. Maresin 1 and resolvin D2 attenuate inflammatory and neuropathic pain through TRPV1 channel modulation, while protectin D1 protects neural tissue from oxidative injury and promotes resolution of allergic airway inflammation.[4]
Clinical Evidence
Cardiovascular Disease: Atherosclerosis is increasingly recognized as a disease of failed resolution rather than simply excess inflammation. Studies in human atherosclerotic plaques have shown an imbalance between pro-inflammatory leukotrienes and pro-resolving lipoxins/resolvins, with vulnerable plaques exhibiting the lowest SPM-to-leukotriene ratios. Restoring this balance — pharmacologically or through omega-3 supplementation — promotes plaque stabilization in preclinical models.[5]
Inflammatory and Autoimmune Disease: SPMs and their stable analogs have been investigated in models of rheumatoid arthritis, inflammatory bowel disease, periodontitis, and asthma. In a landmark clinical proof-of-concept, a topical resolvin E1 analog was developed for dry eye disease, and orally administered SPM-enriched fish oil preparations have shown ability to elevate circulating RvD and RvE species in humans.[2]
Tissue Regeneration: Maresin 1, named for its origin in macrophage mediator in resolution, has emerged as a particularly potent tissue regeneration signal. MaR1 accelerates planarian regeneration and enhances tissue repair in mammalian models of muscle injury and surgical wound healing, suggesting SPMs link inflammation resolution to regenerative biology.[3]
Infection Resolution: Counterintuitively, SPMs improve outcomes in bacterial and viral infection. By enhancing macrophage phagocytosis of pathogens and lowering antibiotic requirements in sepsis models, SPMs demonstrate that resolution agonism is mechanistically distinct from — and potentially superior to — immunosuppression.[3]
Dietary Precursors and the Omega-3 Connection
Because resolvins, protectins, and maresins are biosynthesized from EPA and DHA, dietary intake of these omega-3 fatty acids is the rate-limiting substrate for endogenous SPM production. The cardioprotective and anti-inflammatory effects historically attributed to fish oil are increasingly understood to be mediated, at least in part, through SPM biosynthesis rather than through EPA/DHA themselves acting as pharmacological agents.[5]
This reframes the clinical conversation around omega-3 supplementation: the question is not simply whether EPA and DHA blood levels rise, but whether downstream SPM biosynthesis is intact. Aging, obesity, diabetes, and chronic inflammation all appear to impair the enzymatic machinery (15-LOX, 5-LOX, 12-LOX) responsible for SPM production — a phenomenon termed “resolution failure.”[1]
Safety Profile
Because SPMs are endogenous molecules acting at picomolar to nanomolar concentrations through specific GPCRs, their safety profile in preclinical studies has been favorable. Unlike NSAIDs, which block cyclooxygenase and thereby inhibit not only pro-inflammatory prostaglandins but also the lipid mediator class switch required for resolution, SPMs do not impair host defense. Animal studies have repeatedly shown that SPM administration enhances rather than suppresses bacterial clearance.[3]
Synthetic SPM analogs with improved metabolic stability are in various stages of preclinical and early clinical development. Native SPMs are rapidly inactivated by oxidation at specific hydroxyl groups, which has motivated medicinal chemistry efforts to design fluorinated or methylated analogs resistant to dehydrogenase-mediated inactivation. Long-term human safety data remain limited to omega-3 supplementation trials, which collectively show an excellent tolerability profile.[5]
SPMs vs Conventional Anti-Inflammatory Approaches
vs. NSAIDs: NSAIDs inhibit cyclooxygenase, suppressing prostaglandins broadly. This blocks not only inflammation initiation but also the PGE2/PGD2-dependent class switch to lipoxins and resolvins — potentially delaying resolution. Chronic NSAID use is associated with gastrointestinal, renal, and cardiovascular complications. SPMs, by contrast, are resolution agonists rather than inflammation antagonists.[1]
vs. Glucocorticoids: Corticosteroids broadly suppress immune function, increasing infection risk and producing well-known metabolic, bone, and adrenal toxicities. SPMs accelerate resolution while preserving host defense — a fundamentally different pharmacological category.[3]
vs. Biologic Cytokine Blockade: TNF inhibitors and IL-6 receptor antagonists target individual cytokines downstream of inflammation initiation. SPMs operate one regulatory layer higher — programming the entire resolution phenotype rather than blocking a single signal. The two approaches may ultimately prove complementary in chronic inflammatory disease.[2]
vs. Bulk Omega-3 Supplementation: Standard fish oil delivers EPA and DHA as substrates but does not guarantee that the host’s biosynthetic enzymes will efficiently convert them to SPMs. SPM-enriched marine lipid concentrates and, eventually, synthetic SPM analogs may bypass age- and disease-related resolution failure.[5]
Conclusion
The discovery of specialized pro-resolving mediators has fundamentally reshaped the conceptual framework of inflammation. Resolution is not the absence of inflammation but an active, programmed biological process — and chronic inflammatory disease may be better understood as a failure of resolution than as an excess of activation. Resolvins, protectins, and maresins represent the molecular vocabulary of this resolution program, and harnessing them therapeutically — whether through optimized omega-3 intake, SPM-enriched preparations, or synthetic analogs — opens a path to treating chronic inflammation without immunosuppression.
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Chiang N, Dalli J. “The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.” Seminars in Immunology. 2015;27(3):200-215.
- Chiang N, Serhan CN. “Specialized pro-resolving mediator network: an update on production and actions.” Essays in Biochemistry. 2020;64(3):443-462.
- Serhan CN, Levy BD. “Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.” Journal of Clinical Investigation. 2018;128(7):2657-2669.
- Bäck M, Yurdagul A, Tabas I, Öörni K, Kovanen PT. “Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities.” Nature Reviews Cardiology. 2019;16(7):389-406.
